2153. Addition of Relebactam Increases Susceptibility to Imipenem Alone against Class C β-lactamase-Positive Enterobacterales: Asia/Pacific SMART 2019-2021

BACKGROUND: Imipenem/relebactam (IMI/REL) is a combination of imipenem/cilastatin with the β-lactamase inhibitor relebactam, an inhibitor of class A and C β-lactamases. We evaluated the activity of IMI/REL and comparators against AmpC- and extended-spectrum β-lactamase (ESBL)-producing E. coli and K...

Descripción completa

Detalles Bibliográficos
Autores principales: Lob, Sibylle, Wise, Mark G, Chen, Wei-Ting, Siddiqui, Fakhar, Young, Katherine, Motyl, Mary, Sahm, Daniel F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677764/
http://dx.doi.org/10.1093/ofid/ofad500.1776

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677764/
http://dx.doi.org/10.1093/ofid/ofad500.1776

Ejemplares similares